3681.HK
Price:
$1.48
Market Cap:
$1.61B
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treat...[Read more]
Industry
Biotechnology
IPO Date
2019-11-12
Stock Exchange
HKSE
Ticker
3681.HK
According to SinoMab BioScience Limited’s latest financial reports and current stock price. The company's current PE Ratio is -9.87. This represents a change of 82.58% compared to the average of -5.41 of the last 4 quarters.
The mean historical PE Ratio of SinoMab BioScience Limited over the last ten years is -29.33. The current -9.87 PE Ratio has changed 3.27% with respect to the historical average. Over the past ten years (40 quarters), 3681.HK's PE Ratio was at its highest in in the December 2022 quarter at -2.83. The PE Ratio was at its lowest in in the January 2017 quarter at -111.49.
Average
-29.33
Median
-8.77
Minimum
-104.74
Maximum
-5.58
Discovering the peaks and valleys of SinoMab BioScience Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 227.22%
Maximum Annual PE Ratio = -5.58
Minimum Annual Increase = -85.02%
Minimum Annual PE Ratio = -104.74
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -5.94 | -6.87% |
| 2023 | -6.37 | 14.26% |
| 2022 | -5.58 | -30.61% |
| 2021 | -8.04 | -74.12% |
| 2020 | -31.07 | 227.22% |
| 2019 | -9.50 | -85.02% |
| 2018 | -63.37 | -39.50% |
The current PE Ratio of SinoMab BioScience Limited (3681.HK) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.96
5-year avg
-11.40
10-year avg
-29.33
SinoMab BioScience Limited’s PE Ratio is less than HighTide Therapeutics Inc (-3.68), greater than Mabpharm Limited (-74.69), greater than Shanghai Bio-heart Biological Technology Co., Ltd. (-13.87), less than Cutia Therapeutics (-3.23), less than Immunotech Biopharm Ltd (-5.83), less than Zhaoke Ophthalmology Limited (-5.09), less than 3D Medicines Inc. (-5.82), less than JW (Cayman) Therapeutics Co. Ltd (-1.58), less than Frontage Holdings Corporation (70.83), greater than C-MER Medical Holdings Limited (-17.60),
| Company | PE Ratio | Market cap |
|---|---|---|
| -3.68 | $1.50B | |
| -74.69 | $2.27B | |
| -13.87 | $1.33B | |
| -3.23 | $1.69B | |
| -5.83 | $1.44B | |
| -5.09 | $1.57B | |
| -5.82 | $1.09B | |
| -1.58 | $1.08B | |
| 70.83 | $2.05B | |
| -17.60 | $2.05B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SinoMab BioScience Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SinoMab BioScience Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is SinoMab BioScience Limited's PE Ratio?
How is the PE Ratio calculated for SinoMab BioScience Limited (3681.HK)?
What is the highest PE Ratio for SinoMab BioScience Limited (3681.HK)?
What is the 3-year average PE Ratio for SinoMab BioScience Limited (3681.HK)?
What is the 5-year average PE Ratio for SinoMab BioScience Limited (3681.HK)?
How does the current PE Ratio for SinoMab BioScience Limited (3681.HK) compare to its historical average?